

# The United States vs. Other Countries: Availability of Cancer Medicines Varies

The proposed International Pricing Index Model would set U.S. prices for medicines covered under Medicare Part B based on the pricing policies of 14 foreign governments – many of which set prices artificially low, resulting in severe access restrictions for patients.

	New Cancer Medicines Available	Average Delay in Availability of Cancer Medicines
 Greece	16%	41 months
 Ireland	53%	23 months
 Belgium	55%	25 months
 Czech Republic	55%	24 months
 Italy	58%	21 months
 Japan	58%	23 months
 Canada	59%	14 months
 Finland	61%	14 months
 Netherlands	63%	9 months
 Denmark	64%	11 months
 France	67%	16 months
 Austria	68%	11 months
 United Kingdom	70%	12 months
 Germany	73%	11 months
 United States	96%	0-2 months

Source: PhRMA analysis of IQVIA Analytics Link and FDA, EMA and PMDA data. June 2020. Note: New Active Substances (NASs) approved by the FDA, EMA and/or PMDA and first launched in any country between January 2011 and December 2019. Average delay represents the time in months since global first launch among NASs that have launched in a given country. IQVIA reports only the retail channel for Greece.